Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Prime-LS: a cryoprotectant-free, lyophilized MSC-secretome conferring protection against acute experimental colitis in vivo.

Created on 18 Nov 2026

Authors

Maria Rossello-Gelabert, Camino Garcia-Blasco, Jose Javier Aguirre, Ainhoa Gonzalez-Pujana, Manoli Igartua, Edorta Santos-Vizcaino, Rosa Maria Hernandez

Published in

Trends in biotechnology. Nov 17, 2026. Epub Nov 17, 2026.

Abstract

Ulcerative colitis (UC) is a chronic, immune-mediated disorder characterized by recurrent mucosal inflammation and epithelial damage. Its incidence is rising, while current therapies fail to achieve durable remission due to limited efficacy or adverse effects. Cell-free approaches based on the mesenchymal stromal cell (MSC) secretome offer an alternative with improved safety and scalability. In this study, we present Prime-LS, an excipient-free, off-the-shelf MSC-secretome biologic that retains immunomodulatory activity without cryoprotectants. Prime-LS preserves soluble immunomodulatory mediators and extracellular vesicle populations with characteristic surface markers and vesicular morphology following lyophilization and reconstitution, while forming a homogeneous formulation without visible precipitation or detectable aggregate formation. In vitro, Prime-LS suppressed proliferation of peripheral blood mononuclear cells, while in vivo subcutaneous dosing in a murine colitis model prevented disease onset, preserved mucosal integrity, and normalized inflammation. Together, these findings support Prime-LS as a stable, functionally preserved MSC-secretome formulation with potential for further translational development in UC and other immune-mediated diseases.

PMID:
43045542
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement